Written and medically reviewed by Tae Ho Guak, MD, board-certified neurologist · Reviewed July 2026 · Editorial policy
The headache field advances rapidly. Here are the key updates as of 2026 that actually matter for patients.
1. CGRP Antibodies — 5-Year Safety Data
~7 years since Aimovig, Ajovy, and Emgality launched. New 5-year follow-up data confirms no long-term safety concerns and maintained efficacy. Directly addresses patient worry about taking a newer drug long-term.
2. New Gepants Coming Soon
Oral CGRP antagonists rimegepant and atogepant already in use in the US and Europe. Insurance coverage discussions ongoing in Korea; expected 2026–2027. Key alternative for cardiovascular patients who cannot use triptans.
3. Magnesium — Meta-Analysis Reconfirms Benefit
Two 2024–2025 meta-analyses confirm magnesium supplementation reduces migraine frequency by 30–40% in deficient patients. Now AHS Level A evidence.
4. AHS Guidelines Updated
CGRP antibodies elevated to first-line preventive therapy. Low-dose aspirin recommended for menstrual migraine.
5. Digital Therapeutics
App-based biofeedback and CBT received FDA Breakthrough Device designation. Trials show meaningful reduction in monthly headache days.
→ Back to Headache Information Library
References
- American Headache Society. Consensus statement: integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021–1039.
- Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78(17):1337–1345.
- Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
This article was written and medically reviewed by Tae Ho Guak, MD, a board-certified neurologist. Last reviewed July 2026. See our editorial policy.